ErbB tyrosine kinase receptor inhibitors in breast cancer treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-01-01

AUTHORS

Joan Albanell Mestres, Montserrat Muñoz Mateo, Pedro Gascón

ABSTRACT

The ErbB tyrosine kinase receptor family comprises 4 receptors (HER1 [EGFR/ErbB1], HER2 [ErbB2], HER3 [ErbB3] and HER4 [ErbB4]), and at least 10 ligands. Pre-clinical and clincial studies have indicated that members of this family have important roles in breast cancer development and progression, and which leads to the concept of targeting ErbB receptors as a promising treatment strategy. Trastuzumab, an anti-HER2 antibody, provided the first definitive evidence for the clinical efficacy of targeting an ErbB receptor in patients with breast cancer. Over the past 5 years, much interest has been generated as a result of the development of orally-administered ErbB tyrosine kinase receptor inhibitors. Pre-clinical and early clinical studies with these agents are reviewed here. More... »

PAGES

12-21

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02710297

DOI

http://dx.doi.org/10.1007/bf02710297

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090311415


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS, Hospital Clinic, c/Villarroel, 170, 08036, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.410458.c", 
          "name": [
            "Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS, Hospital Clinic, c/Villarroel, 170, 08036, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mestres", 
        "givenName": "Joan Albanell", 
        "id": "sg:person.01271155641.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271155641.84"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Mateo", 
        "givenName": "Montserrat Mu\u00f1oz", 
        "type": "Person"
      }, 
      {
        "familyName": "Gasc\u00f3n", 
        "givenName": "Pedro", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1025467500433", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034197538", 
          "https://doi.org/10.1023/a:1025467500433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205794", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050596563", 
          "https://doi.org/10.1038/sj.onc.1205794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1204082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011731995", 
          "https://doi.org/10.1038/sj.onc.1204082"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4615-0081-0_21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047034338", 
          "https://doi.org/10.1007/978-1-4615-0081-0_21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1018762216147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023566342", 
          "https://doi.org/10.1023/a:1018762216147"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-01-01", 
    "datePublishedReg": "2004-01-01", 
    "description": "The ErbB tyrosine kinase receptor family comprises 4 receptors (HER1 [EGFR/ErbB1], HER2 [ErbB2], HER3 [ErbB3] and HER4 [ErbB4]), and at least 10 ligands. Pre-clinical and clincial studies have indicated that members of this family have important roles in breast cancer development and progression, and which leads to the concept of targeting ErbB receptors as a promising treatment strategy. Trastuzumab, an anti-HER2 antibody, provided the first definitive evidence for the clinical efficacy of targeting an ErbB receptor in patients with breast cancer. Over the past 5 years, much interest has been generated as a result of the development of orally-administered ErbB tyrosine kinase receptor inhibitors. Pre-clinical and early clinical studies with these agents are reviewed here.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02710297", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1035367", 
        "issn": [
          "1699-048X", 
          "1699-3055"
        ], 
        "name": "Clinical and Translational Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "tyrosine kinase receptor inhibitor", 
      "receptor inhibitors", 
      "ErbB tyrosine kinase receptor family", 
      "ErbB receptors", 
      "breast cancer treatment", 
      "breast cancer development", 
      "early clinical studies", 
      "promising treatment strategy", 
      "anti-HER2 antibody", 
      "clincial studies", 
      "tyrosine kinase receptor family", 
      "clinical efficacy", 
      "treatment strategies", 
      "breast cancer", 
      "clinical studies", 
      "cancer development", 
      "cancer treatment", 
      "first definitive evidence", 
      "receptor family", 
      "receptors", 
      "definitive evidence", 
      "inhibitors", 
      "trastuzumab", 
      "patients", 
      "cancer", 
      "important role", 
      "progression", 
      "antibodies", 
      "efficacy", 
      "treatment", 
      "study", 
      "years", 
      "agents", 
      "family", 
      "evidence", 
      "development", 
      "role", 
      "strategies", 
      "members", 
      "results", 
      "ligands", 
      "interest", 
      "concept", 
      "kinase receptor family", 
      "ErbB tyrosine kinase receptor inhibitors", 
      "kinase receptor inhibitors"
    ], 
    "name": "ErbB tyrosine kinase receptor inhibitors in breast cancer treatment", 
    "pagination": "12-21", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090311415"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02710297"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02710297", 
      "https://app.dimensions.ai/details/publication/pub.1090311415"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_394.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02710297"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02710297'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02710297'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02710297'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02710297'


 

This table displays all metadata directly associated to this object as RDF triples.

137 TRIPLES      22 PREDICATES      77 URIs      63 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02710297 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N30558461b3ee41dc88334c315c8323e9
4 schema:citation sg:pub.10.1007/978-1-4615-0081-0_21
5 sg:pub.10.1023/a:1018762216147
6 sg:pub.10.1023/a:1025467500433
7 sg:pub.10.1038/35052073
8 sg:pub.10.1038/sj.onc.1204082
9 sg:pub.10.1038/sj.onc.1205794
10 schema:datePublished 2004-01-01
11 schema:datePublishedReg 2004-01-01
12 schema:description The ErbB tyrosine kinase receptor family comprises 4 receptors (HER1 [EGFR/ErbB1], HER2 [ErbB2], HER3 [ErbB3] and HER4 [ErbB4]), and at least 10 ligands. Pre-clinical and clincial studies have indicated that members of this family have important roles in breast cancer development and progression, and which leads to the concept of targeting ErbB receptors as a promising treatment strategy. Trastuzumab, an anti-HER2 antibody, provided the first definitive evidence for the clinical efficacy of targeting an ErbB receptor in patients with breast cancer. Over the past 5 years, much interest has been generated as a result of the development of orally-administered ErbB tyrosine kinase receptor inhibitors. Pre-clinical and early clinical studies with these agents are reviewed here.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree false
16 schema:isPartOf N658c0a7cde7d42c1b10fca9f6497cdb8
17 Nb59f6a4d801945b79603d63e10d4b0da
18 sg:journal.1035367
19 schema:keywords ErbB receptors
20 ErbB tyrosine kinase receptor family
21 ErbB tyrosine kinase receptor inhibitors
22 agents
23 anti-HER2 antibody
24 antibodies
25 breast cancer
26 breast cancer development
27 breast cancer treatment
28 cancer
29 cancer development
30 cancer treatment
31 clincial studies
32 clinical efficacy
33 clinical studies
34 concept
35 definitive evidence
36 development
37 early clinical studies
38 efficacy
39 evidence
40 family
41 first definitive evidence
42 important role
43 inhibitors
44 interest
45 kinase receptor family
46 kinase receptor inhibitors
47 ligands
48 members
49 patients
50 progression
51 promising treatment strategy
52 receptor family
53 receptor inhibitors
54 receptors
55 results
56 role
57 strategies
58 study
59 trastuzumab
60 treatment
61 treatment strategies
62 tyrosine kinase receptor family
63 tyrosine kinase receptor inhibitor
64 years
65 schema:name ErbB tyrosine kinase receptor inhibitors in breast cancer treatment
66 schema:pagination 12-21
67 schema:productId N316c0eadc7e24c779746cca963c47f8a
68 N3ca51bd8f6704e789f207cb9533b1e91
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090311415
70 https://doi.org/10.1007/bf02710297
71 schema:sdDatePublished 2022-01-01T18:14
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher Ncf855a40a6794228a2d15c2e6aa3387d
74 schema:url https://doi.org/10.1007/bf02710297
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N022346c9030840a1bec031896984b777 schema:familyName Mateo
79 schema:givenName Montserrat Muñoz
80 rdf:type schema:Person
81 N30558461b3ee41dc88334c315c8323e9 rdf:first sg:person.01271155641.84
82 rdf:rest Nfa413d6298874cf0a485c7704f833db4
83 N316c0eadc7e24c779746cca963c47f8a schema:name doi
84 schema:value 10.1007/bf02710297
85 rdf:type schema:PropertyValue
86 N3ca51bd8f6704e789f207cb9533b1e91 schema:name dimensions_id
87 schema:value pub.1090311415
88 rdf:type schema:PropertyValue
89 N658c0a7cde7d42c1b10fca9f6497cdb8 schema:volumeNumber 6
90 rdf:type schema:PublicationVolume
91 Nb59f6a4d801945b79603d63e10d4b0da schema:issueNumber 1
92 rdf:type schema:PublicationIssue
93 Nc0c1a1b2ebb14f7ba28f3f32554dc1d9 schema:familyName Gascón
94 schema:givenName Pedro
95 rdf:type schema:Person
96 Ncf855a40a6794228a2d15c2e6aa3387d schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 Nf68656b8acbe4d3781762a99a83043f1 rdf:first Nc0c1a1b2ebb14f7ba28f3f32554dc1d9
99 rdf:rest rdf:nil
100 Nfa413d6298874cf0a485c7704f833db4 rdf:first N022346c9030840a1bec031896984b777
101 rdf:rest Nf68656b8acbe4d3781762a99a83043f1
102 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
103 schema:name Medical and Health Sciences
104 rdf:type schema:DefinedTerm
105 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
106 schema:name Oncology and Carcinogenesis
107 rdf:type schema:DefinedTerm
108 sg:journal.1035367 schema:issn 1699-048X
109 1699-3055
110 schema:name Clinical and Translational Oncology
111 rdf:type schema:Periodical
112 sg:person.01271155641.84 schema:affiliation grid-institutes:grid.410458.c
113 schema:familyName Mestres
114 schema:givenName Joan Albanell
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271155641.84
116 rdf:type schema:Person
117 sg:pub.10.1007/978-1-4615-0081-0_21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047034338
118 https://doi.org/10.1007/978-1-4615-0081-0_21
119 rdf:type schema:CreativeWork
120 sg:pub.10.1023/a:1018762216147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023566342
121 https://doi.org/10.1023/a:1018762216147
122 rdf:type schema:CreativeWork
123 sg:pub.10.1023/a:1025467500433 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034197538
124 https://doi.org/10.1023/a:1025467500433
125 rdf:type schema:CreativeWork
126 sg:pub.10.1038/35052073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565592
127 https://doi.org/10.1038/35052073
128 rdf:type schema:CreativeWork
129 sg:pub.10.1038/sj.onc.1204082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011731995
130 https://doi.org/10.1038/sj.onc.1204082
131 rdf:type schema:CreativeWork
132 sg:pub.10.1038/sj.onc.1205794 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050596563
133 https://doi.org/10.1038/sj.onc.1205794
134 rdf:type schema:CreativeWork
135 grid-institutes:grid.410458.c schema:alternateName Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS, Hospital Clinic, c/Villarroel, 170, 08036, Barcelona, Spain
136 schema:name Medical Oncology Department, ICMHO & Unitat de Patologia Mamaria & IDIBAPS, Hospital Clinic, c/Villarroel, 170, 08036, Barcelona, Spain
137 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...